Company
Headquarters: Beijing, China
Employees: 992
CN¥20.89 Billion
CNY as of Jan. 1, 2026
US$2.98 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.89 B |
| EBITDA | CN¥383.3 M |
| Gross Profit TTM | CN¥1.76 B |
| Profit Margin | -15.29% |
| Operating Margin | -32.62% |
| Quarterly Revenue Growth | -46.30% |
Sinocelltech Group Ltd has the following listings and related stock indices.
Stock: SSE: 688520